Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
about
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerGonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysisThe role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UKIn search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growthAdvances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyAndrogen receptor as a driver of therapeutic resistance in advanced prostate cancer.Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Management of metastatic hormone-sensitive prostate cancer.New advances in genitourinary cancer: evidence gathered in 2014.Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trialsDegarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patientsEfficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.Therapeutic outcomes of the LHRH antagonists.[Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017.Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.Degarelix for treating advanced hormone-sensitive prostate cancer
P2860
Q26747782-1A602EC2-82F8-4D0C-A677-0A6BAE1ABDB1Q26777150-99E5F9A8-45B7-4919-A1C2-733BA0128D78Q28072710-8B6954BF-142E-417D-86CA-1690829F8105Q28545022-D6B88BFF-5A5B-4358-AA6C-04374BEA8EDBQ28829239-934B4D7B-530D-41C2-9235-FD17A76248BFQ33775723-6BA03C75-8133-4A99-98A2-7317565C5C86Q35870468-389CC441-3D71-4B45-9A43-F0ABE700F0D5Q36748502-87CE0EED-CF5E-4588-AC7D-27538E00A8D6Q38353835-8CB0C96E-0E1D-4AA6-B36D-2D3EC16D8421Q38557894-94208473-D581-442A-87A4-CB8F8C3380EAQ38691255-9EA43DA4-FE61-4705-B1A6-A14D164363DEQ38798811-793A1612-48CD-41BF-91BE-E2EC76FC32F2Q38803264-945246A8-F037-4F81-BEA3-347D74540040Q38892158-45787A48-9CAB-491D-8373-1D1109797774Q39006967-0D2C671B-A7E3-4EE1-B22A-5AAF94D55091Q39236911-9EDA3CD1-E053-4353-99BF-535E01EDC051Q39247489-AA25E13D-F503-42AF-9B0E-71F0A04B07D0Q40797796-61AA4918-9969-4CE5-9E59-B7A349A416A2Q41555086-A92A3ACF-4767-4426-AF16-24106375AF9BQ41600644-4A1B1C95-FA6D-45C0-A292-6B3A07E6564AQ47148733-91B68F95-67DB-49FC-880F-5133D8FE5444Q47859553-95B7DFB9-8DAB-4DF6-96B9-1DD43BC2BE1FQ53651883-373D0084-BBE8-428B-9DD5-701B100E2A2FQ53734447-F5AEFC68-8F8E-4841-8860-FF1228D8373BQ55024078-AAA33DA3-6C9D-49E3-A10B-9A3D69FD2327Q55068843-FF8EB93E-1A55-4512-8C7A-C8E6F33CB489Q57776096-EC62A27F-3088-4753-96EB-7E4A2253EC93
P2860
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Disease control outcomes from ...... ne-releasing hormone agonists.
@ast
Disease control outcomes from ...... ne-releasing hormone agonists.
@en
type
label
Disease control outcomes from ...... ne-releasing hormone agonists.
@ast
Disease control outcomes from ...... ne-releasing hormone agonists.
@en
prefLabel
Disease control outcomes from ...... ne-releasing hormone agonists.
@ast
Disease control outcomes from ...... ne-releasing hormone agonists.
@en
P2093
P1433
P1476
Disease control outcomes from ...... ne-releasing hormone agonists.
@en
P2093
Anders Malmberg
Bertrand Tombal
Bo-Eric Persson
Cathrina Karup
E David Crawford
Kurt Miller
Neal Shore
P304
P356
10.1016/J.EURURO.2013.12.063
P407
P577
2014-01-09T00:00:00Z